Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 2001
Issue release date: May–June 2001
Dement Geriatr Cogn Disord 2001;12:226–231
(DOI:10.1159/000051262)

Comparison of Brain Perfusion in Corticobasal Degeneration and Alzheimer’s Disease

Okuda B. · Tachibana H. · Kawabata K. · Takeda M. · Sugita M.
Fifth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

To compare brain perfusion between corticobasal degeneration (CBD) and Alzheimer’s disease (AD), we measured regional cerebral blood flow (rCBF) semiquantitatively with single-photon emission computed tomography in 10 patients with CBD and 16 with AD. There was no significant difference in age or illness duration between the patients with CBD and AD. Mini-Mental State Examination scores were significantly lower in the AD patients than in the CBD patients. All CBD patients showed asymmetric akinetic-rigid syndrome and limb apraxia. Four CBD patients were demented, and 1 AD patient had parkinsonism. Compared with 12 age-matched control subjects, the average of the left and right rCBF values for the CBD patients was significantly reduced in the prefrontal, anterior cingulate (AC), medial premotor, sensorimotor (SM), posterior parietal (PP) and superior temporal (ST) cortices as well as in the basal ganglia (BG) and thalamus (Th), while the prefrontal, PP and ST cortices were significantly hypoperfused in the AD patients. In the CBD patients, rCBF was significantly less in the AC and SM cortices, and in the Th and BG, and significantly greater in the PP cortex than in the AD patients. Interhemispheric differences of rCBF in the inferior prefrontal and SM cortices were significantly greater in the CBD patients than the AD patients. It is concluded that rCBF comparison may aid in differentiating CBD from AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Neary D: Frontotemporal degeneration, Pick disease, and corticobasal degeneration. Arch Neurol 1997;54:1425–1427.
  2. Gibb WRG, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989;112:1171–1092.

    External Resources

  3. Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, Black S: Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–1212.
  4. Rinne JO, Lee MS, Thompson PD, Marsden CD: Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;117:1183–1196.

    External Resources

  5. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, Agid Y: The neuropsychological pattern of corticobasal degeneration. Comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–1483.
  6. Bergeron C, Pollanen MS, Weyer L, Black SE, Lang AE: Unusual clinical presentations of cortical-basal ganglionic degeneration. Ann Neurol 1996;40:893–900.
  7. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS: Corticobasal degeneration: Neuropathologic and clinical heterogeneity. Neurology 1997;48:959–969.
  8. Geldmacher DS, Whitehouse PJ: Differential diagnosis of Alzheimer’s disease. Neurology 1997;48(suppl 6): S2–S9.
  9. Ball JA, Lantos PL, Jackson M, Marsden CD, Scadding JW, Rossor MN: Alien hand sign in association with Alzheimer’s histopathology. J Neurol Neurosurg Psychiatry 1993;56:1020–1023.
  10. Giannakopoulous P, Duc M, Gold G, Hof PR, Michel JP, Bouras C: Pathologic correlates of apraxia in Alzheimer disease. Arch Neurol 1998;55:689–695.
  11. Lang AE, Bergeron C, Pollanen MS, Ashby P: Parietal Pick’s disease mimicking cortical-basal ganglionic degeneration. Neurology 1994;44:1436–1440.
  12. Litvan I, Cummings JL, Mega M: Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717–721.
  13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  14. Okuda B, Tanaka H, Tomino Y, Kawabata K, Tachibana H, Sugita M: The role of the left somatosensory cortex in human hand movement. Exp Brain Res 1995;106:493–498.

    External Resources

  15. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Thieme Medical, 1988.
  16. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RSJ: Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991;114:541–556.

    External Resources

  17. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JG, Strother SC, Cederbaum J, Greene P, Fahn S, Powers JM, Rottenberg DA: The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:856–862.
  18. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y: Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992;7:348–354.
  19. Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M: Slowly progressive limb-kinetic apraxia with a decrease in unilateral cerebral blood flow. Acta Neurol Scand 1992;86:76–81.
  20. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC: Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson’s disease and normal controls. Mov Disord 1995;10:179–187.
  21. Okuda B, Tachibana H, Takeda M, Kawabata K, Sugita M, Fukuchi M: Focal cortical hypoperfusion in corticobasal degeneration demonstrated by three-dimensioned surface display with 123I-IMP: A possible cause of apraxia. Neuroradiology 1995;37:642–644.
  22. Ferraro A: Presenile psychoses; in Arieti S (ed): Americal Handbook of Psychiatry. New York, Basic Books, 1969, vol 2, pp 1046–1077.
  23. Kamo H, McGeer PL, Harrop R, McGeer EG, Calne DB, Martin WRW, Pate BD: Positron emission tomography and histopathology in Pick’s disease. Neurology 1987;37:439–445.
  24. Haxby JV, Grady CL, Koss E, Horwitz B, Schapiro M, Friedland RP, Rapoport SI: Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology 1998;38:1853–1863.
  25. Tachibana H, Kawabata K, Tomino Y, Sugita M, Fukuchi M: Brain perfusion imaging in Parkinson’s disease and Alzheimer’s disease demonstrated by three-dimensional surface display with 123I-Iodoamphetamine. Dementia 1993;4:334–341.
  26. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI: Positron emission tomography in Alzheimer’s disease. Neurology 1986;36:879–887.

    External Resources

  27. Martin A, Cox C, Brouwers P, Fedio P: A note on different patterns of impaired and preserved cognitive abilities and their relation to episodic memory deficits in Alzheimer’s patients. Brain Language 1985;26:181–185.
  28. Johnson KA, Holman L, Rosen J, Nagel S, English RJ, Growdon JH: Iofetamine 123I single photon emission computed tomography is accurate in the diagnosis of Alzheimer’s disease. Arch Intern Med 1990;150:752–756.
  29. Benson DF, Cummings JL, Tsai SY: Angular gyrus syndrome simulating Alzheimer’s disease. Arch Neurol 1982;39:616–620.

    External Resources

  30. Lezak MD: Neuropsychological Assessment, ed 4. New York, Oxford University Press, 1995.
  31. Grossman M, Payer F, Onishi K, D’Esposito M, Morrison D, Sadek A, Alavi A: Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer’s disease. Neurology 1998;50:157–163.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50